Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

The International Society of CNS Clinical Trials Methodology (ISCTM) Working Group on Rare Disease/Orphan Drug Development is dedicated to improving and streamlining trials to best develop new treatments for rare diseases. The rarity of these disorders requires a drug development strategy that diffe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Innovations in clinical neuroscience 2021-10, Vol.18 (10-12), p.15-22
Hauptverfasser:	Busner, Joan, Pandina, Gahan, Domingo, SilviaZaragoza, Berger, Anna-Karin, Acosta, Maria T, Fisseha, Nahome, Horrigan, Joseph, Ivkovic, Jelena, Jacobson, William, Revicki, Dennis, Villalta-Gil, Victoria
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!